Skip to content
2000
Volume 17, Issue 6
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

Rexinoids are selective ligands for the nuclear receptors known as RXRs. They do not bind to the receptors for all-trans-retinoic acid (RARs). Many new rexinoids have been synthesized and then assayed for their ability to suppress proliferation of cancer cells, to inhibit activation of inflammatory cells of the tumor microenvironment, and to prevent carcinogenesis in animal models relevant to human disease. Here we review the literature on the effects of 4 such rexinoids: bexarotene, LG100268, LG101506, and NRX194204. These rexinoids also have potent synergistic effects when used in combination with other active pharmacological agents, and practical clinical applications would benefit from these actions.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/1568026616666160617090702
2017-03-01
2025-07-11
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/1568026616666160617090702
Loading

  • Article Type:
    Review Article
Keyword(s): Bexarotene; Carcinogenesis; Combination therapy; Inflammation; LG100268; RXR
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test